A Novel Strategy to Improve the Therapeutic Efficacy of Gemcitabine for Non-Small Cell Lung Cancer by the Tumor-Penetrating Peptide iRGD
Fig 3
Therapeutic efficacy of Gemcitabine combined with iRGD for human NSCLC xenografts.
(A) The tumor volume curve during treatment. Arrows indicate the time of injection. The day when treatment started was recorded as day 0. Tumor volume was measured once every three days until day 30. (B) Average tumor weight of each group at the end of treatment. (C) The body weight shift curve of the mice during the experiment. n = 6. Error bars, mean ± SD; ns, not significant; *** p < 0.001.